Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | F10 | P00742 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL660361 | 0.89 | GSK3B (0.42) | KMT2AMAPK1LMNAGSK3BMEN1 | |
| SCHEMBL659354 | 0.89 | ALDH1A1 (0.33) | KMT2AMAPK1MEN1POLBMAPT | |
| SCHEMBL7800030 | 0.87 | KMT2A (0.39) | KMT2AMAPK1LMNAGSK3BMEN1 | |
| SCHEMBL287773 | 0.82 | ALDH1A1 (0.39) | KMT2ALMNAMEN1POLBMAPT | |
| SCHEMBL27854963 | 0.80 | GSK3B (0.36) | KMT2AMAPK1LMNAGSK3BMEN1 | |
| SCHEMBL661083 | 0.80 | ALDH1A1 (0.39) | KMT2AMAPK1LMNAMEN1POLB | |
| SCHEMBL660526 | 0.80 | KAT6A (0.35) | KMT2AMAPK1MEN1MAPTKDM4E | |
| SCHEMBL660291 | 0.78 | KMT2A (0.38) | KMT2AMAPK1LMNAMEN1POLB | |
| SCHEMBL658639 | 0.78 | ALDH1A1 (0.39) | KMT2AMAPK1LMNAGSK3BMAPT | |
| SCHEMBL27550907 | 0.78 | GSK3B (0.36) | KMT2AMAPK1LMNAGSK3BMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046317-A1 | NOVEL HETEROCYCLIC COMPOUNDS | DUTT CHAITANYA (IN) | 2012-02-23 | — | — | US | claimed |
| US-20120046317-A1 | NOVEL HETEROCYCLIC COMPOUNDS | DUTT CHAITANYA (IN) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046317-A1 | NOVEL HETEROCYCLIC COMPOUNDS | AGER, REN, AGT | KMT2A 4512/4885MAPK1 1750/4885LMNA 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.